Refractory Multiple Myeloma - Pipeline Review, H2

2015 Now Available at iData Insights

Refractory Multiple Myeloma - Pipeline Review, H2 2015 Summary Global Markets Direct s, Refractory Multiple
Myeloma - Pipeline Review, H2 2015 , provides an overview of the Refractory Multiple Myeloma s therapeutic
pipeline. This report provides comprehensive information on the therapeutic development for Refractory Multiple
Myeloma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism
of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and
press releases. It also reviews key players involved in the therapeutic development for Refractory Multiple Myeloma
and special features on late-stage and discontinued projects. Global Markets Direct s report features investigational
drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data
and information sourced from Global Markets Direct s proprietary databases, Company/University websites, SEC
filings, investor presentations and featured press releases from company/university sites and industry-specific third
party sources, put together by Global Markets Direct s team. Drug profiles/records featured in the report undergoes
periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest
set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical
trials registries tracking ensure that the most recent developments are captured on a real time basis. The report
enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class
products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of
data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of
Refractory Multiple Myeloma - The report reviews key pipeline products under drug profile section which includes,
product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The
report reviews key players involved in the therapeutics development for Refractory Multiple Myeloma and enlists all
their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review
of the Refractory Multiple Myeloma products under development by companies and universities/research institutes
based on information derived from company and industry-specific sources - Pipeline products coverage based on
various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed
assessment of monotherapy and combination therapy pipeline projects - Coverage of the Refractory Multiple
Myeloma pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals
relating related to pipeline products Reasons to buy - Provides strategically significant competitor information,
analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially
strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic
initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse
types of therapeutics under development for Refractory Multiple Myeloma - Plan mergers and acquisitions effectively
by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by
understanding Refractory Multiple Myeloma pipeline depth and focus of Indication therapeutics - Develop and design
in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to
enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued
projects and understanding the factors that drove them from pipeline
Browse Complete Report with TOC @ http://www.idatainsights.com/reports-landingpage.php?id=124191/refractory-multiple-myeloma-pipeline-review-h2-2015
To Get Sample Copy of Report visit @ http://www.idatainsights.com/reports-landingpage.php?id=124191/refractory-multiple-myeloma-pipeline-review-h2-2015
Table of Contents
Table of Contents
2 List of Tables
6 List of Figures
8 Introduction
9 Global Markets Direct Report Coverage
9 Refractory Multiple Myeloma Overview

10 Therapeutics Development
11 Pipeline Products for Refractory Multiple Myeloma - Overview
11 Pipeline Products for Refractory Multiple Myeloma - Comparative Analysis
12 Refractory Multiple Myeloma - Therapeutics under Development by Companies
13 Refractory Multiple Myeloma - Therapeutics under Investigation by Universities/Institutes
18 Refractory Multiple Myeloma - Pipeline Products Glance
19 Late Stage Products
19 Clinical Stage Products
20 Early Stage Products
21 Refractory Multiple Myeloma - Products under Development by Companies
22 Refractory Multiple Myeloma - Products under Investigation by Universities/Institutes
27 Refractory Multiple Myeloma - Companies Involved in Therapeutics Development
28 4SC AG
28 AbbVie Inc.
29 Acetylon Pharmaceuticals, Inc.
30 Altor BioScience Corporation
31 Arno Therapeutics, Inc.
32 Array BioPharma Inc.
33 Astellas Pharma Inc.
34 Astex Pharmaceuticals, Inc.
35 Biotest AG
36 Boehringer Ingelheim GmbH
37 Bristol-Myers Squibb Company
38 Calithera Biosciences, Inc.
39 Celgene Corporation
40 Cellectar Biosciences, Inc.
41 Cleave Biosciences
42 CureTech Ltd.
43 Curis, Inc.
44 Dicerna Pharmaceuticals, Inc.
45 Exelixis, Inc.
46 F. Hoffmann-La Roche Ltd.
47 GlaxoSmithKline Plc

48 Immunomedics, Inc.
49 Jasco Pharmaceuticals, LLC.
50 Johnson & Johnson
51 JW Pharmaceutical Corporation
52 Karyopharm Therapeutics, Inc.
53 MedImmune, LLC
54 Merck & Co., Inc.
55 Millennium Pharmaceuticals, Inc.
56 MorphoSys AG
57 Novartis AG 58 Oncolytics Biotech Inc.
59 Oncopeptides AB
60 Onyx Pharmaceuticals, Inc.
61 Otsuka Holdings Co., Ltd.
62 Patrys Limited 63 Pfizer Inc.
64 Pharma Mar, S.A.
65 Prolexys Pharmaceuticals, Inc.
66 Sanofi
67 Sigma-Tau S.p.A.
68 Stemline Therapeutics, Inc.
69 Sumitomo Dainippon Pharma Co., Ltd.
70 Synta Pharmaceuticals Corp.
71 Threshold Pharmaceuticals, Inc.
72 Vivolux AB
73 Refractory Multiple Myeloma - Therapeutics Assessment
74 Assessment by Monotherapy Products
74 Assessment by Combination Products
75 Assessment by Target
76 Assessment by Mechanism of Action
81 Assessment by Route of Administration
85 Assessment by Molecule Type
87 Drug Profiles
89 4SC-202 - Drug Profile
89 ABBV-838 - Drug Profile

91 ACP-196 - Drug Profile

92 ACY-241 - Drug Profile
95 afuresertib hydrochloride - Drug Profile
97 alisertib - Drug Profile
99 alpelisib - Drug Profile
103 ALT-801 - Drug Profile
105 ALT-803 - Drug Profile
108 amrubicin hydrochloride - Drug Profile
110 AR-42 - Drug Profile
112 AT-7519 - Drug Profile
114 AT-9283 - Drug Profile
117 B-701 - Drug Profile
119 bendamustine hydrochloride - Drug Profile
120 BI-836909 - Drug Profile
123 BMS-986016 - Drug Profile
124 cabozantinib s-malate - Drug Profile
125 carfilzomib - Drug Profile
129 CB-5083 - Drug Profile
133 CB-839 - Drug Profile
134 CC-90002 - Drug Profile
136 Cell Therapy to Target CD
138 for Relapsed and Refractory Multiple Myeloma - Drug Profile
137 CUDC-907 - Drug Profile
138 CWP-291 - Drug Profile
140 daratumumab - Drug Profile
142 DCRM-1711 - Drug Profile
145 DKN-01 - Drug Profile
147 elotuzumab - Drug Profile
149 erismodegib - Drug Profile
151 evofosfamide - Drug Profile
154 filanesib - Drug Profile
161 ganetespib - Drug Profile
163 GSK-2857916 - Drug Profile

167 I131-CLR1404 - Drug Profile

168 ibrutinib - Drug Profile
170 indatuximab ravtansine - Drug Profile
177 inebilizumab - Drug Profile
179 ipilimumab - Drug Profile
181 isatuximab - Drug Profile
185 ixazomib citrate - Drug Profile
187 JP-11646 - Drug Profile
191 LCL-161 - Drug Profile
192 linsitinib - Drug Profile
194 marizomib - Drug Profile
196 Melflufen - Drug Profile
198 milatuzumab - Drug Profile
200 MOR-202 - Drug Profile
202 MV-NIS - Drug Profile
204 NL-101 - Drug Profile
206 OPB-51602 - Drug Profile
207 oprozomib - Drug Profile
208 palbociclib - Drug Profile
210 PATSM-6 - Drug Profile
214 pelareorep - Drug Profile
216 pembrolizumab - Drug Profile
221 pidilizumab - Drug Profile
230 PIM-447 - Drug Profile
232 plerixafor - Drug Profile
233 plitidepsin - Drug Profile
235 PRLX-93936 - Drug Profile
237 Recombinant Protein for Oncology - Drug Profile
239 ricolinostat - Drug Profile
241 roneparstat - Drug Profile
243 RRX-001 - Drug Profile
244 sapanisertib - Drug Profile
246 selinexor - Drug Profile

248 SL-401 - Drug Profile

254 trametinib dimethyl sulfoxide + uprosertib - Drug Profile
256 ulocuplumab - Drug Profile
258 urelumab - Drug Profile
260 vemurafenib - Drug Profile
262 venetoclax - Drug Profile
266 VLX-1570 - Drug Profile
269 vorinostat - Drug Profile
271 Refractory Multiple Myeloma - Recent Pipeline Updates
275 Refractory Multiple Myeloma - Dormant Projects
443 Refractory Multiple Myeloma - Discontinued Products
447 Refractory Multiple Myeloma - Product Development Milestones
448 Featured News & Press Releases
448 Appendix 456 Methodology
456 Coverage
456 Secondary Research
456 Primary Research
456 Expert Panel Validation
456 Contact Us
456 Disclaimer
Read More http://www.idatainsights.com/reports-landing-page.php?id=124191/refractory-multiple-myeloma-pipelinereview-h2-2015
About Us:
iData Insights which operates under Precision Research and Consulting Private Limited is a leading market research
information aggregator and marketing research consulting firm. We conduct both primary and secondary research.
Our work does not end with research it is also involved in distributing reports for different companies . We provide
actionable recommendations and provide our expertise for business success today and tomorrow. It is our goal to be
a partner to our clients in the exploration and discovery, and then be their guide in the implementation of changes that
will make a difference to their bottom line.

Contact Us:
iData Insights
Tel: 1-866-237-2965
Web: http://www.idatainsights.com
Email: info@idatainsights.com

About iData Insights

We work around the clock until our clients are completely satisfied with their promised results. It is our mission to
provide timely services coupled with acute client care to create a long-lasting relationship with you. We deliver on our
promise to provide results that are essential to the success of your company. We believe that by doing so, we will
earn the trust of our clients for future projects.